losartan-potassium and Hypertension--Malignant

Topics: Adult; Anemia; Anemia, Hemolytic; Anemia, Hypochromic; Blood Platelets; Blood Urea Nitrogen; Bone Marrow Cells; Chronic Disease; Erythrocytes; Erythrocytes, Abnormal; Erythropoiesis; Erythropoietin; Feedback; Female; Hemolysis; Hemostasis; Humans; Hypertension, Malignant; Iron; Kidney; Kidney Concentrating Ability; Kidney Diseases; Kidney Failure, Chronic; Male; Middle Aged; Oxygen Consumption; Plasma Volume; Uremia

Topics: Abdominal Neoplasms; Adolescent; Erythropoietin; Female; Humans; Hypertension, Malignant; Neoplasms, Multiple Primary; Paraganglioma, Extra-Adrenal; Perioperative Care; Polycythemia; Renal Artery Obstruction

Four patients on regular dialysis treatment whose blood pressure was well controlled, developed malignant hypertension while receiving maintenance recombinant human erythropoietin (r-Hu-EPO). None of these patients had a haematocrit greater than 35% at any stage, and clinically, none had any evidence of fluid overload. Initially, they were all managed by stopping r-Hu-EPO and intensification of antihypertensive therapy. However, none of the patients responded, and venesection of 500 ml of blood was performed in each case with swift and sustained response.

Topics: Adult; Anemia; Blood Pressure; Blood Volume; Bloodletting; Erythropoietin; Female; Humans; Hypertension, Malignant; Kidney Failure, Chronic; Middle Aged

Topics: Bloodletting; Erythropoietin; Humans; Hypertension, Malignant; Recombinant Proteins

Topics: Bloodletting; Erythropoietin; Humans; Hypertension, Malignant

Topics: Acute Disease; Adult; Anuria; Blood Cell Count; Blood Transfusion; Bone Marrow Examination; Erythropoiesis; Erythropoietin; Female; Hematocrit; Hemoglobinometry; Humans; Hypertension, Malignant; Male; Nephrectomy; Pyelonephritis; Renal Dialysis; Reticulocytes; Urea; Uremia